Tvardi Therapeutics (TVRD) Capital Expenditures: 2013-2024
Historic Capital Expenditures for Tvardi Therapeutics (TVRD) over the last 12 years, with Dec 2024 value amounting to $1.0 million.
- Tvardi Therapeutics' Capital Expenditures fell 94.29% to $28,000 in Q3 2017 from the same period last year, while for Sep 2017 it was $127,000, marking a year-over-year decrease of 80.61%. This contributed to the annual value of $1.0 million for FY2024, which is 55.96% down from last year.
- Latest data reveals that Tvardi Therapeutics reported Capital Expenditures of $1.0 million as of FY2024, which was down 55.96% from $2.4 million recorded in FY2023.
- In the past 5 years, Tvardi Therapeutics' Capital Expenditures ranged from a high of $2.4 million in FY2023 and a low of $39,000 during FY2021.
- Over the past 3 years, Tvardi Therapeutics' median Capital Expenditures value was $1.0 million (recorded in 2024), while the average stood at $1.2 million.
- As far as peak fluctuations go, Tvardi Therapeutics' Capital Expenditures plummeted by 88.83% in 2021, and later soared by 5,423.26% in 2023.
- Over the past 5 years, Tvardi Therapeutics' Capital Expenditures (Yearly) stood at $349,000 in 2020, then crashed by 88.83% to $39,000 in 2021, then rose by 10.26% to $43,000 in 2022, then soared by 5,423.26% to $2.4 million in 2023, then slumped by 55.96% to $1.0 million in 2024.